AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22106979 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil 0 mg / Pioglitazone 0 mg
Number of subjects: 377
Study 19424032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 140
Study 19424032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 17545701 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (sd-NVP) prophylaxis
Number of subjects: 740
Study 15273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Five different simple questioning techniques
Number of subjects: 200
Study 15273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous questions regarding satisfaction
Number of subjects: 200
Study 15273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating using grades known from the German school system (1-6)
Number of subjects: 200
Study 15273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS; 0-100 mm)
Number of subjects: 200
Study 15273929 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-9 questionnaire
Number of subjects: 200
Study 11212969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol 80 mg/day + L-arginine 21 g/day
Number of subjects: 3
Study 11212969 — intervention group
Group type: COMPARATOR
Intervention: Cortisol 80 mg/day + Placebo
Number of subjects: 3
Study 9548602 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-ILP
Number of subjects: 832
Study 9548602 — intervention group
Group type: COMPARATOR
Intervention: TM-ILP
Number of subjects: 832
Study 9548602 — intervention group
Group type: EXPERIMENTAL
Intervention: M-ILP
Number of subjects: 832
Study 7753427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (80-120 mg daily)
Number of subjects: 30
Study 7753427 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40-60 mg daily)
Number of subjects: 30
Study 7753427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30
Study 7753427 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30
Study 3058537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (75 mg orally at night)
Number of subjects: 60
Study 3058537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30607817 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (Nerlynx®) for 12 months
Number of subjects: 0
Study 30607817 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (Nerlynx®)
Number of subjects: 0
Study 28749729 — intervention group
Group type: COMPARATOR
Intervention: General message (same message as provided to all White participants)
Number of subjects: 1513
Study 28749729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 of 4 alternate messages framing the need for participation in terms of race and/or health disparities
Number of subjects: 1513
Study 28749729 — intervention group
Group type: COMPARATOR
Intervention: General message
Number of subjects: 1513
Study 28749729 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial framing
Number of subjects: 1513
Study 25584995 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use hydrophilic coated catheter
Number of subjects: 66
Study 25584995 — intervention group
Group type: COMPARATOR
Intervention: Multiple use polyvinylchloride catheter
Number of subjects: 66
Study 23415937 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA for 20 min)
Number of subjects: 36
Study 23415937 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36
Study 21235615 — intervention group
Group type: EXPERIMENTAL
Intervention: Open healing (OH)
Number of subjects: 21
Study 21235615 — intervention group
Group type: COMPARATOR
Intervention: Submerged healing (SH)
Number of subjects: 21
Study 21235615 — intervention group
Group type: COMPARATOR
Intervention: Both OH and SH
Number of subjects: 21
Study 18854803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 (Dicoflor Elle, Dicofarm, Roma, Italy) administered orally, two tablets daily for 15 days
Number of subjects: 50
Study 18854803 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy followed by Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 50
Study 17194242 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Training (AT)
Number of subjects: 22
Study 17194242 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 22
Study 12599005 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroradiologists using CTA
Number of subjects: 60
Study 12599005 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroradiologists using MRA
Number of subjects: 60
Study 12599005 — intervention group
Group type: COMPARATOR
Intervention: Other observers using CTA
Number of subjects: 60
Study 12599005 — intervention group
Group type: COMPARATOR
Intervention: Other observers using MRA
Number of subjects: 60
Study 10937511 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (30 microg/ml zinc)
Number of subjects: 256
Study 10937511 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (80 microg/ml zinc)
Number of subjects: 256
Study 10937511 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 256
Study 10937511 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 256
Study 8765253 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous closed drainage system
Number of subjects: 197
Study 8765253 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous closed drainage system
Number of subjects: 197
Study 8765253 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous closed drainage system with prophylactic antibiotics
Number of subjects: 197
Study 8765253 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous closed drainage system without prophylactic antibiotics
Number of subjects: 197
Study 1576070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) at varying inspiratory flows (34 to 88 l min‐1)
Number of subjects: 10
Study 1576070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) with prior exhalation through the device
Number of subjects: 10
Study 1576070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled via Turbohaler (TBH) at approximately 34 l min‐1
Number of subjects: 10
Study 6399986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX)
Number of subjects: 0
Study 30934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 3881
Study 30934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in upper age quartile (60.3‐67.6 years)
Number of subjects: 3881
Study 30934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in two highest age quartiles (54.6‐60.2 and 60.3‐67.6 years)
Number of subjects: 3881
Study 30934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3881
Study 30934155 — intervention group
Group type: COMPARATOR
Intervention: Men who smoked
Number of subjects: 3881
Study 30934155 — intervention group
Group type: COMPARATOR
Intervention: Women who smoked
Number of subjects: 3881
Study 30934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and women sensitized to both grass and perennial allergens
Number of subjects: 3881
Study 30420347 — intervention group
Group type: EXPERIMENTAL
Intervention: MYmind programme delivered by trained healthcare professionals
Number of subjects: 140
Study 30420347 — intervention group
Group type: COMPARATOR
Intervention: CBT programme
Number of subjects: 140
Study 27339736 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis (20-50 IU kg(‐1) two or three times per week for 12 months)
Number of subjects: 62
Study 27339736 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis (twice-weekly vs. three times-weekly dosing)
Number of subjects: 62
Study 27339736 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 during major surgeries
Number of subjects: 62
Study 27339736 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 prophylaxis
Number of subjects: 62
Study 25048508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tramadol 100 mg in 500 mL 0.9%NaCl one hour before the procedure
Number of subjects: 74
Study 25048508 — intervention group
Group type: COMPARATOR
Intervention: 500 mL 0.9%NaCl (control group)
Number of subjects: 74
Study 25048508 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesia (diclofenac 75 mg i.m.) when required
Number of subjects: 74
Study 22158143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment at 25 Hz, 35 Hz, and 45 Hz with low amplitude (1 mm) and high amplitude (3.1 mm)
Number of subjects: 20
Study 22158143 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a soft pad during vibration treatment
Number of subjects: 20
Study 22158143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration treatment (various frequencies and amplitudes)
Number of subjects: 20
Study 21273805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 520
Study 21273805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 18041883 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg oral suspension 3 times/day for a maximum of 16 weeks
Number of subjects: 246
Study 16195948 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal classroom‐based intervention targeting disruptive behavior
Number of subjects: 664
Study 16195948 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 664
Study 12119249 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus irbesartan
Number of subjects: 154
Study 12119249 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 154
Study 11028251 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin i.v. bolus
Number of subjects: 0
Study 11028251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0
Study 11028251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study of bolus dosing
Number of subjects: 0
Study 8986182 — intervention group
Group type: EXPERIMENTAL
Intervention: Countercurrent heat exchangers (n = 25)
Number of subjects: 50
Study 8986182 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study 1446565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 60
Study 1446565 — intervention group
Group type: COMPARATOR
Intervention: No-stimulus control
Number of subjects: 60
Study 6367690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 204
Study 6367690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-DST HYPAC measures (morning plasma cortisol, urine free cortisol, CSF cortisol levels)
Number of subjects: 204
Study 6367690 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and body weight correlation
Number of subjects: 204
Study 31677670 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance with miniscrews
Number of subjects: 13
Study 31677670 — intervention group
Group type: COMPARATOR
Intervention: Standard Herbst appliance without miniscrews
Number of subjects: 13
Study 29376858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET), 90 minutes of aerobic and strength training, 72 treatment sessions over 6 months
Number of subjects: 34
Study 29376858 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Treatment (CT), 90 minutes of cognitive stimuli
Number of subjects: 34
Study 26162946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with rosuvastatin (5 mg for 4 weeks, then 10 mg for 8 weeks)
Number of subjects: 111
Study 26162946 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy with rosuvastatin (2.5 mg for 12 weeks)
Number of subjects: 111
Study 25842456 — intervention group
Group type: EXPERIMENTAL
Intervention: New 2-step etch & rinse adhesive and a new nano-filled ormocer
Number of subjects: 50
Study 25842456 — intervention group
Group type: COMPARATOR
Intervention: Composite (control)
Number of subjects: 50
Study 22198596 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries exams by trained, calibrated examiners
Number of subjects: 437
Study 19997018 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage
Number of subjects: 12
Study 19997018 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + protein beverage (CHO + Pro)
Number of subjects: 12
Study 18617126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) - Duragesic 50 microg/h, applied approximately 10 hours before induction of general anesthesia
Number of subjects: 30
Study 18617126 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) programmed in the PACU
Number of subjects: 30
Study 15975304 — intervention group
Group type: EXPERIMENTAL
Intervention: Breviscapine intravenously dripped for 2 treatment courses
Number of subjects: 76
Study 15975304 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine, captopril/uropidil
Number of subjects: 76
Study 19753721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 120
Study 19753721 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 120
Study 19753721 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 120
Study 16021880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of didanosine plus stavudine plus nevirapine with hydroxyurea
Number of subjects: 22
Study 16021880 — intervention group
Group type: COMPARATOR
Intervention: Combination of didanosine plus stavudine plus nevirapine without hydroxyurea
Number of subjects: 22
Study 8614136 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 243
Study 8614136 — intervention group
Group type: COMPARATOR
Intervention: CyA alone
Number of subjects: 243
Study 8614136 — intervention group
Group type: COMPARATOR
Intervention: CyA+LI
Number of subjects: 243
Study 8614136 — intervention group
Group type: COMPARATOR
Intervention: CyA group
Number of subjects: 243
Study 29503305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuma na Uchizi intervention (cash transfers, access to savings account, life-skills training)
Number of subjects: 101
Study 29503305 — intervention group
Group type: COMPARATOR
Intervention: Control group (receiving outpatient care)
Number of subjects: 101
Study 27603344 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 210
Study 24879492 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 116
Study 24879492 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 116
Study 23094269 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerging vital roots
Number of subjects: 10
Study 23094269 — intervention group
Group type: COMPARATOR
Intervention: Control area (no submerged roots)
Number of subjects: 10
Study 20427778 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (800 IU daily)
Number of subjects: 247
Study 20427778 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 247
Study 20427778 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 247
Study 20427778 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 247
Study 17991257 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard practice plus monitoring of depth of anaesthesia with M-Entropy
Number of subjects: 72
Study 17991257 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 72
Study 17991257 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 72
Study 15898476 — intervention group
Group type: EXPERIMENTAL
Intervention: Points condition
Number of subjects: 10
Study 15898476 — intervention group
Group type: COMPARATOR
Intervention: No-points condition
Number of subjects: 10
Study 12242596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine as the experimental drug
Number of subjects: 103
Study 12242596 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine as the control drug
Number of subjects: 103
Study 9819017 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (with HCTZ 12.5 mg increased to 25 mg)
Number of subjects: 140
Study 9819017 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg (increased to 60 mg and 90 mg)
Number of subjects: 140
Study 7707420 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized breast cancer risk counseling
Number of subjects: 200
Study 7707420 — intervention group
Group type: COMPARATOR
Intervention: General health counseling (control)
Number of subjects: 200
Study 2547410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg daily for 21-28 days)
Number of subjects: 18
Study 2547410 — intervention group
Group type: COMPARATOR
Intervention: Control (before fluconazole therapy)
Number of subjects: 18
Study 871601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic grey-scale image
Number of subjects: 0
Study 871601 — intervention group
Group type: COMPARATOR
Intervention: Other type of ultrasonic image
Number of subjects: 0
Study 30415083 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including case management, reminders, educational materials, workshops, and audit and feedback reports.
Number of subjects: 1624
Study 30415083 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 1624
Study 27483481 — intervention group
Group type: EXPERIMENTAL
Intervention: Action planning
Number of subjects: 7399
Study 27483481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward
Number of subjects: 7399
Study 27483481 — intervention group
Group type: COMPARATOR
Intervention: Thank you (control)
Number of subjects: 7399
Study 25346329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture and discussion plus case-based learning (n = 35)
Number of subjects: 101
Study 25346329 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture and discussion (n = 66)
Number of subjects: 101
Study 25346329 — intervention group
Group type: COMPARATOR
Intervention: CPE nurses (n = 59)
Number of subjects: 101
Study 23020923 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 21
Study 23020923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21695251 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication-defective Ad5 gag/pol/nef vaccine
Number of subjects: 0
Study 19229545 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days minimal‐residue (low fibre intake) pre‐operative diet (n = 42)
Number of subjects: 83
Study 19229545 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation the day before the operation (n = 41)
Number of subjects: 83
Study 17240581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length measurement with a cut-off value of ≤ 2.5 cm
Number of subjects: 200
Study 17240581 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal os diameter measurement
Number of subjects: 200
Study 12547889 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (0.1 units/kg body wt)
Number of subjects: 11
Study 12547889 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.1 units/kg body wt)
Number of subjects: 11
Study 12547889 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 11
Study 12547889 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 11
Study 10872995 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldspathic ceramic inlays (Vita Mark II)
Number of subjects: 16
Study 10872995 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ceramic inlays (Dicor MGC)
Number of subjects: 16
Study 10872995 — intervention group
Group type: COMPARATOR
Intervention: Both types of inlays (Feldspathic and Glass ceramic)
Number of subjects: 16
Study 9432302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unstable angina pectoris
Number of subjects: 43
Study 9432302 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study 1549030 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (2% grade increment)
Number of subjects: 9
Study 1549030 — intervention group
Group type: COMPARATOR
Intervention: Protocol D (8% grade increment)
Number of subjects: 9
Study 4025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ba-wei-wan (hachimijiogan)
Number of subjects: 24
Study 4025217 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of Ba-wei-wan
Number of subjects: 24
Study 31542473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic decompressive laminectomy
Number of subjects: 64
Study 31542473 — intervention group
Group type: COMPARATOR
Intervention: Microscopic decompressive laminectomy
Number of subjects: 64
Study 29309314 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone traction group
Number of subjects: 125
Study 29309314 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine traction group
Number of subjects: 125
Study 29309314 — intervention group
Group type: COMPARATOR
Intervention: PT only group
Number of subjects: 125
Study 27464321 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage therapy (SMT)
Number of subjects: 47
Study 27464321 — intervention group
Group type: COMPARATOR
Intervention: Light touch control
Number of subjects: 47
Study 24843973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination electroacupuncture anesthesia (group B)
Number of subjects: 60
Study 24843973 — intervention group
Group type: COMPARATOR
Intervention: Regular general anesthesia (group A)
Number of subjects: 60
Study 22640930 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/d n-3 PUFAs
Number of subjects: 138
Study 22640930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g/d n-3 PUFAs
Number of subjects: 138
Study 22640930 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 138
Study 22640930 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 138
Study 20850381 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus dexrazoxane
Number of subjects: 205